Form 4: Silicon Laboratories Director Sells 2,000 Shares Under 10b5-1 Trading Plan

William G. Bock, a director at Silicon Laboratories, sold 2,000 shares of common stock at an average price of $140.77 per share under a pre-arranged 10b5-1 trading plan.

Summary

• William G. Bock, a director at Silicon Laboratories, executed a sale of 2,000 shares of the company's common stock.
• The transaction occurred on January 22, 2025.
• The shares were sold at a weighted average price of $140.77, with individual prices ranging from $140 to $141.67.
• The sale was conducted under a pre-established 10b5-1 trading plan.
• Following the transaction, Mr. Bock directly owns 32,115 shares of Silicon Laboratories common stock.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an insider stock sale, which is neither positive nor negative in itself. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on any new information.

Industry Context

This is a routine disclosure of an insider transaction, which is common for publicly traded companies. It provides transparency into the trading activities of company directors.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The use of a 10b5-1 trading plan is a common method for insiders to sell shares while avoiding accusations of trading on non-public information.
• Comparable companies would also have similar filings when directors or officers trade their company's stock.

Stakeholder Impact

• The sale of shares by a director may have a minor impact on investor sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

insider trading, Form 4, stock sale, 10b5-1 plan, Silicon Laboratories, director